LipoScience Inc. Newest Member of Nation’s Leading Lab Association
The American Clinical Laboratory Association ( www.clinical-labs.org ) announced today that LipoScience ( www.liposcience.com ) has become a member of the American Clinical Laboratory Association (ACLA).
The Raleigh, N.C.-based company is dedicated to developing and marketing clinical diagnostic applications using Nuclear Magnetic Resonance (NMR) Spectroscopy. LipoScience provides patients and health care professionals with information to diagnose and manage risk of cardiovascular disease and other chronic diseases. The company’s NMR LipoProfile® test ( www.lipoprofile.com ) provides new insight into managing heart disease risk and patient response to therapy, including statins.
“I am excited about the addition of LipoScience to ACLA’s membership,” said ACLA President Alan Mertz. “After visiting LipoScience’s facility in Raleigh, North Carolina, recently, I can report that LipoScience is a great example of the clinical diagnostic innovations that ACLA’s member companies are developing. These innovations are providing new ways to prevent and/or manage disease, and help patients lead longer and healthier lives. With the addition of LipoScience, ACLA’s membership now stands at 24, up more than 80 percent in the past one-and-one-half years,” Mertz said.
About ACLA
Founded in 1971, the ACLA is the clinical laboratory industry’s leading advocate providing effective communication with Congress, regulatory bodies, other health care organizations and the public.
A not-for-profit association, the ACLA represents the nation’s leading national and regional clinical laboratories on key issues of common concern, including federal and state government reimbursement and regulatory policies.
About LipoScience, Inc.
Headquartered in Raleigh, N.C., LipoScience develops and markets new clinical applications of NMR spectroscopy in the areas of cardiovascular disease and metabolic disorders. Its flagship product, the NMR LipoProfile blood test, was introduced for clinical research in 1997 and for use in patient care in 1999.
The test provides a direct and accurate count of the numbers of atherogenic LDL particles (LDL-P) and VLDL particles of different size, as well as the numbers of protective HDL particles. It is ideally suited for patients who are being considered for or who are currently on LDL-lowering therapy – patients considered to be at moderately high or high risk for having a cardiovascular event. The lipoprotein particle information is used as an adjunct to traditional cholesterol measures to help physicians assess and manage their patient’s risk of cardiovascular disease more effectively.
In addition, the NMR LipoProfile test is used in a wide range of clinical studies conducted by government, academic and pharmaceutical company researchers. By illuminating relationships between lipoprotein particles and cardiovascular disease, diabetes and other disorders, these studies seek to develop more effective prevention and treatment strategies.
Results previously reported from the Cardiovascular Health Study, Women’s Health Study, PLAC-I and VA-HIT, among others, have all shown LDL-P to predict future cardiovascular disease better than LDL-C. The present findings from the Framingham Offspring Study confirm and extend these earlier reports.
###
